Symptom-Triggered Testing Can ID Low Disease Burden in Ovarian Cancer
By Elana Gotkine HealthDay Reporter
FRIDAY, Aug. 16, 2024 -- Symptom-triggered testing can identify women with high-grade serous ovarian cancer with low disease burden, according to a study published online Aug. 13 in the International Journal of Gynecological Cancer.
Fong Lien Audrey Kwong, from The Pan-Birmingham Gynaecological Cancer Centre at the Sandwell and West Birmingham NHS Trust in the United Kingdom, and colleagues examined the potential value of symptom-triggered testing in the detection of early-stage disease or low tumor burden for women presenting via the fast-track pathway and who were diagnosed with high-grade serous ovarian cancer. Women presenting with symptoms suspicious for ovarian cancer received a CA125 blood test and an ultrasound scan in the event of an abnormal CA125 level. If either test was abnormal, the women were referred to secondary care within two weeks.
Overall, 119 of 1,741 participants (6.8 percent) recruited via the fast-track pathway were diagnosed with high-grade serous ovarian cancer. The researchers found that 112 of these participants (94.1 percent) had a performance status of 0 and 1; 30 (25.2 percent) were diagnosed with stages I/II; and low-to-moderate disease distribution was identified in 77 (64.7 percent). Overall, 73 and 18 patients achieved complete and optimal cytoreduction (61.3 and 15.1 percent, respectively). The extent of disease was low, moderate, high, and not available in 36.1, 28.6, 26.9, and 8.4 percent, respectively. Seventy-eight women (65.5 percent) with high-grade serous ovarian cancer underwent primary debulking surgery.
"Symptom-triggered testing may help to identify women with low disease burden, potentially contributing to high complete cytoreduction rates and improving survival outcomes in these patients," the authors write.
Several authors disclosed ties to the pharmaceutical and other industries.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-08-17 03:15
Read more
- ASA: Risk for Postoperative Delirium Increased With Poor and Worsening Sleep
- Cognitive Therapy, Modafinil, Combo All Beneficial for Multiple Sclerosis Fatigue
- First Cases of Sexually Transmitted Ringworm Reported in the U.S.
- Nitrofurantoin, Cranberry Products May Cut UTI Episodes in Children
- Ozempic Curbs Kidney Disease in Obese People Without Diabetes
- Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions